Sir -I think that Mr Fayers' criticism is extremely harsh. While I accept that the study was not perfect, it was an honest attempt to investigate palliative treatment for an unusual and particularly horrific disease. Because the disease is rare the number of patients was limited, and in a singlecentre trial there was little that could be done about this. I accept that Gehan's rule was not used correctly and certainly accept that the trial was small. Only enough patients were available to conduct the first stage of Gehan's procedure, for which 14 patients would be enough to give a 95% probability of yielding at least one response if the response rate was 20%. Between the two treatments we had 16 patients, for which the probability of at least one response if the response was 20% was 97.2%. Equivalently, there was a probability of 95% of finding at least one response if the response rate was as low as 17%. In fact one (partial) response was obtained (among the patients receiving cisplatinum).
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I would like to draw Mr Fayers' attention to the comments we made at the end of the paper. Because of the long and unpredictable survival even in the terminal stages of the disease, response rates are perhaps a better guide to treatment efficacy than is survival. While I accept his points about survival it was felt that the categories of response to treatment were more important and were quoted in full. Mr Fayers seems to feel that we did not dare to quote confidence intervals. This was an omission and I am grateful to him for pointing this out. The 95% confidence interval for the mean survival of the cisplatinum group was 110-765 days and in the epirubicin group the 95% confidence interval was 0-531 days. Incidentally, a Mann-Whitney test used to compare the two sets of survival times (all of which were uncensored) also yield a non-significant difference (P= 0.36 
